Cellumed Co

Cellumed Co Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Cellumed Co (049180.KQ) as of Nov 5, 2026 is 1.02. In the previous year, Net Debt to Free Cash Flow Ratio was 0.01 — a change of 7,325.72% (higher).

Net Debt/FCF

1.02

YoY

7,325.72%

Last updated:

Net Debt to Free Cash Flow Ratio of Cellumed Co is 2024 1.02 . Net Debt to Free Cash Flow Ratio of Cellumed Co was 2023 0.01 . It decreases by 7,325.72% higher compared to the previous year.

The Cellumed Co Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2017
-1.08 KRW
Jan 1, 2018
0.01 KRW
Jan 1, 2019
4.18 KRW
Jan 1, 2020
3.71 KRW
Jan 1, 2021
1.67 KRW
Jan 1, 2022
0.27 KRW
Jan 1, 2023
0.01 KRW
Jan 1, 2024
1.02 KRW
The Cellumed Co Net Debt/FCF history
YEARNet Debt/FCFYoY
1.02+7,325.72%
0.01-94.95%
0.27-83.69%
1.67-55.04%
3.71-11.13%
4.18+44,385.88%
0.01-100.87%
-1.08+221.51%
-0.34-85.10%
-2.25+376.22%
-0.47—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cellumed Co Stock analysis

What does Cellumed Co do? Cellumed Co Ltd manufactures and distributes medical devices and biomaterials, including allografts for tissue repair, bone sponges, bone powders, and demineralized bone matrixes (DBMs) for bone regeneration. The company also produces biosimilars like bone morphogenetic protein 2 (BMP2) reagents and medical devices such as spinal fixation systems, joint replacements, and navigation systems. Cellumed sells these products domestically in Seoul and internationally to overseas markets. Cellumed’s primary customers are healthcare providers and medical institutions that require tissue repair solutions, bone regeneration products, and advanced medical devices. The company’s product portfolio targets orthopedic and spinal care segments, with a focus on biomaterials and surgical tools. Its biosimilars, including BMP2 reagents, cater to specialized medical applications requiring bone growth stimulation. The company generates revenue through direct sales of its medical devices and biomaterials to hospitals, clinics, and international distributors. Cellumed’s domestic market in Seoul serves local healthcare facilities, while its overseas sales expand its reach to global medical markets. The firm’s product range supports both routine and complex surgical procedures in orthopedics and spinal care. Cellumed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellumed Co stock

Net Debt to Free Cash Flow Ratio of Cellumed Co is 1.02 in 2024.

Net Debt to Free Cash Flow Ratio of Cellumed Co changed from 0.01 to 1.02, representing a 7,325.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Cellumed Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Cellumed Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cellumed Co

All Key Metrics — Cellumed Co